LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Axsome Therapeutics Inc

Fermé

SecteurSoins de santé

111.62 0.97

Résumé

Variation du prix de l'action

24h

Actuel

Min

110.55

Max

111.95

Chiffres clés

By Trading Economics

Revenu

15M

-59M

Ventes

2.7M

121M

BPA

-1.216

Marge bénéficiaire

-48.914

Employés

712

EBITDA

14M

-57M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+59.38% upside

Dividendes

By Dow Jones

Prochains Résultats

4 août 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-171M

5.3B

Ouverture précédente

110.65

Clôture précédente

111.62

Sentiment de l'Actualité

By Acuity

50%

50%

166 / 380 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Weak Bearish Evidence

Axsome Therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

6 juin 2025, 14:31 UTC

Résultats

New York State Retirement Fund Posts 5.84% Annual Investment Return

6 juin 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

6 juin 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

6 juin 2025, 20:33 UTC

Résultats

These Stocks Moved the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6 juin 2025, 19:36 UTC

Market Talk

Oil Futures Post Solid Weekly Gains -- Market Talk

6 juin 2025, 19:28 UTC

Market Talk

U.S. Natural Gas Futures Rise on Demand Expectations -- Market Talk

6 juin 2025, 18:46 UTC

Market Talk

Gold Faced With Tariff Uncertainty Offset by ETF Withdrawals -- Market Talk

6 juin 2025, 18:02 UTC

Market Talk

U.S. Oil Rig Count Continues to Decline -- Market Talk

6 juin 2025, 16:35 UTC

Résultats

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6 juin 2025, 16:34 UTC

Résultats

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6 juin 2025, 16:21 UTC

Market Talk

Canadian Unemployment Set to Continue Feel Trade War Pressures -- Market Talk

6 juin 2025, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

6 juin 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

6 juin 2025, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

6 juin 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

6 juin 2025, 16:07 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

6 juin 2025, 16:07 UTC

Market Talk

Base Metal Prices Slide But Copper Set to End Week Higher -- Market Talk

6 juin 2025, 15:53 UTC

Market Talk

Mexican Inflation Seen Rising in May -- Market Talk

6 juin 2025, 15:36 UTC

Market Talk

Dollar's Boost From U.S. Jobs Data Could Be Limited -- Market Talk

6 juin 2025, 15:36 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

6 juin 2025, 15:33 UTC

Market Talk

Gold Futures Slide After Jobs Data Surprises to Upside -- Market Talk

6 juin 2025, 15:16 UTC

Market Talk

Tesla Showing Signs of Weakness in Key Regions -- Market Talk

6 juin 2025, 15:05 UTC

Market Talk

Silver at its Highest In Nearly 15 Years -- Market Talk

6 juin 2025, 14:35 UTC

Market Talk

Weakening Canadian Job Market Seen Keeping BoC in Easing Mode -- Market Talk

6 juin 2025, 14:28 UTC

Market Talk

Bitcoin Rises After Above-Forecast U.S. Jobs Data -- Market Talk

6 juin 2025, 14:28 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

6 juin 2025, 14:28 UTC

Market Talk

Canada's Job Market Weakens But Not Seen Collapsing -- Market Talk

6 juin 2025, 14:15 UTC

Market Talk

Oil Rises on U.S.-China Talks Optimism -- Market Talk

6 juin 2025, 14:12 UTC

Résultats

Palantir and Super Micro Computer Stocks Rise as Broadcom Posts Strong AI Revenue -- Barrons.com

6 juin 2025, 14:09 UTC

Résultats

Broadcom, the $1 Trillion Stock You Shouldn't Ignore, Makes AI Investment Case -- Barrons.com

Comparaison

Variation de prix

Axsome Therapeutics Inc prévision

Objectif de Prix

By TipRanks

59.38% hausse

Prévisions sur 12 Mois

Moyen 178.36 USD  59.38%

Haut 210 USD

Bas 148 USD

Basé sur 16 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

16 ratings

16

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

107.24 / 112.29Support & Résistance

Court Terme

Weak Bearish Evidence

Moyen Terme

Neutral Evidence

Long Terme

Strong Bullish Evidence

Sentiment

By Acuity

166 / 380Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Axsome Therapeutics Inc

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.